May 29, 2026 - Hangzhou Sciwind Biosciences Co., Ltd. ("Sciwind Biosciences"), a biopharmaceutical company focused on the discovery and development of innovative therapies for metabolic diseases, today announced that the company will present head-to-head clinical data of Ecnoglutide versus semaglutide, as well as preclinical progress of its next-generation weight loss and metabolic pipeline, at the 86th Scientific Sessions of the American Diabetes Association (ADA). The annual meeting will be held in New Orleans, USA, June 5-8, 2026 (Central Daylight Time).

Presentation Details

Title: Efficacy and Safety of cAMP-Biased Ecnoglutide vs. Unbiased Semaglutide in Adults with Obesity: Twenty-Week Results from a Multicenter, Randomized, Open-Label, Phase 2 Study

Poster Number: 2849-LB

Presenter: Professor Linong Ji, Peking University People's Hospital

Date/Time: Sunday, June 7, 2026, 1:30 PM-2:30 PM CDT

Location: Hall D-E

Format: Late Breaking Poster Presentation

Title: A β-klotho Antibody Conjugated to GLP-1/GCG/GIP Triple Agonist Demonstrates Robust Body Weight Reduction and Metabolic Improvement in Obese Rodents and Nonhuman Primates

Session Theme: Obesity/Integrated Physiology-GLP-1 and What Else? Preclinical Obesity Studies

Presentation Number: IP-OR02-1.5/1324-OR

Presenter: Haixia Zou, PhD

Date/Time: June 8, 2026, 2:45 PM-3:00 PM CDT

Format: Oral Presentation

Dr. Hai Pan, Founder and CEO of Sciwind Biosciences, stated: "As the world's first approved cAMP-biased GLP-1 receptor agonist, the head-to-head clinical data of Ecnoglutide versus semaglutide has been selected as a Late Breaking abstract and will be presented as a poster at the 2026 ADA Scientific Sessions. ADA is the most influential academic conference in the global metabolic field, and inclusion in the Late Breaking category represents the cutting-edge scientific breakthroughs in this area. Meanwhile, we will deliver an oral presentation on the breakthrough preclinical progress of our next-generation innovative pipeline, a β-klotho antibody-conjugated GLP-1/GCG/GIP triple agonist. We are proud to share these breakthroughs with the global scientific community. These findings underscore the distinctive strengths of Sciwind's technology platforms and lay critical groundwork for the next generation of metabolic disease therapies."

About Ecnoglutide

Ecnoglutide injection, originally discovered and developed by Sciwind Biosciences, is the world's first approved cAMP-biased GLP-1 receptor agonist enhancing clinical efficacy and accessibility. Ecnoglutide injection has currently been approved for two indications in China: adult weight management with overweight or obesity and the treatment of adult type 2 diabetes. From Phase I through Phase III, Ecnoglutide injection has consistently demonstrated a favorable safety profile and strong efficacy, with the findings published in leading metabolic journals, underscoring its potential as a promising therapy for patients with metabolic diseases.

About Sciwind Biosciences

Sciwind Biosciences is a commercial-stage biopharmaceutical company, dedicated to addressing the unmet medical needs in the field of weight management and metabolic diseases. Sciwind has established a robust pipeline anchored by the lead asset, Ecnoglutide (XW003). It has developed multiple proprietary technology platforms, including biased agonist discovery platform, long-acting and oral peptide delivery platforms, and has identified a series of drug candidates based on these core technology platforms. Sciwind has built an extensive pipeline targeting GLP-1 and synergistic pathways, offering both injectable and oral treatment solutions to deliver sustainable and high-quality therapies for patients with metabolic diseases.

For more information, please visit www.sciwindbio.com.

Contacts

General Inquiries: PR@sciwindbio.com

Business Development: BD@sciwindbio.com